TapImmune to Present at the LD Micro Invitational in Los Angeles on June 7, 2016

JACKSONVILLE, FL, June 6, 2016 / TapImmune,Inc. (TPIV), a clinical-stage immune-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced it will be presenting at the LD Micro Invitational on Tuesday, June 7 at 9:00am. Dr. John N. Bonfiglio, a TapImmune Board member and Strategic Advisor, will be giving the presentation and meeting with investors.

The presentation will cover recent company developments including TapImmune’s Phase 2 ovarian cancer trial with AstraZeneca and Sloan Kettering Cancer Institute.

Interested investors may view TapImmune’s profile here: http://www.ldmicro.com/profile/TPIV.

About TapImmune Inc.

TapImmune Inc. is an immuno-oncology company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The Company’s peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients’ killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company’s technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company’s website at markertherapeutics.com for details.

Forward-Looking Statement Disclaimer

This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements”. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.


TapImmune Inc.,

Glynn Wilson, Ph.D.

Chairman & CEO